Neuphoria Therapeutics (NEUP) Retained Earnings (2021 - 2025)
Historic Retained Earnings for Neuphoria Therapeutics (NEUP) over the last 5 years, with Q4 2025 value amounting to -$186.4 million.
- Neuphoria Therapeutics' Retained Earnings fell 313.4% to -$186.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$186.4 million, marking a year-over-year decrease of 313.4%. This contributed to the annual value of -$178.3 million for FY2025, which is N/A changed from last year.
- Per Neuphoria Therapeutics' latest filing, its Retained Earnings stood at -$186.4 million for Q4 2025, which was down 313.4% from -$188.3 million recorded in Q3 2025.
- In the past 5 years, Neuphoria Therapeutics' Retained Earnings registered a high of -$120.0 million during Q4 2021, and its lowest value of -$188.3 million during Q3 2025.
- Moreover, its 5-year median value for Retained Earnings was -$178.3 million (2025), whereas its average is -$162.6 million.
- Per our database at Business Quant, Neuphoria Therapeutics' Retained Earnings plummeted by 1025.23% in 2023 and then crashed by 313.4% in 2025.
- Quarter analysis of 5 years shows Neuphoria Therapeutics' Retained Earnings stood at -$120.0 million in 2021, then decreased by 3.46% to -$124.1 million in 2022, then fell by 10.25% to -$136.9 million in 2023, then crashed by 32.05% to -$180.7 million in 2024, then fell by 3.13% to -$186.4 million in 2025.
- Its last three reported values are -$186.4 million in Q4 2025, -$188.3 million for Q3 2025, and -$178.3 million during Q2 2025.